Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H15NO8S2 |
Molecular Weight | 437.444 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)OC1=CC=C(C=C1)C(C2=CC=C(OS(O)(=O)=O)C=C2)C3=CC=CC=N3
InChI
InChIKey=UJIDKYTZIQTXPM-UHFFFAOYSA-N
InChI=1S/C18H15NO8S2/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)
Molecular Formula | C18H15NO8S2 |
Molecular Weight | 437.444 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Picosulfuric acid (as sodium picosulfate) is a contact laxative, which is used in combination with: magnesium oxide, and anhydrous citric acid for cleansing of the colon as a preparation for colonoscopy in adults. Sodium picosulfate is a prodrug. It has no significant direct physiological effect on the intestine. But it is hydrolyzed by colonic bacteria to form an active metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic peristalsis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: colonic mucosa |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PREPOPIK Approved UsePREPOPIK (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults. Launch Date2012 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.3 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
21.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
209 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
275 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
7.4 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
PubMed
Title | Date | PubMed |
---|---|---|
Oral sodium phosphate solution: a review of its use as a colorectal cleanser. | 2004 |
|
Screening procedure for detection of stimulant laxatives and/or their metabolites in human urine using gas chromatography-mass spectrometry after enzymatic cleavage of conjugates and extractive methylation. | 2005 Apr |
|
[Distigmine bromide improves chronic intestinal pseudo-obstruction in a case of MELAS]. | 2007 Apr |
|
Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. | 2007 Dec 3 |
|
Randomized clinical trial comparing sodium picosulfate with mannitol on the preparation FOR colonoscopy in hospitalized patients. | 2007 Jul-Sep |
|
Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. | 2009 |
|
A review of laxative therapies for treatment of chronic constipation in older adults. | 2010 Dec |
|
Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. | 2010 Sep |
Sample Use Guides
PREPOPIK ((sodium picosulfate, magnesium oxide, and anhydrous citric acid), supplied as a powder, must be reconstituted with cold water right before its use. There are two dosing regimens, each requires two separate dosing times: The preferred method is the “Split Dose” method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy. The alternative method is the “Day Before” method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy). Additional fluids must be consumed after every dose in both dosing regimens. Instruct patients to consume only clear liquids (no solid food or milk) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy. Instruct patients that if they experience severe bloating, distention, or abdominal pain following the first dose, delay the second dose until their symptoms resolve.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1507649
Sodium picosulfate was biotransformed by intestinal flora that produced a novel sulfotransferase (not sulfatase). The biotransformation was activated by adding phenolic compounds such as phenol, acetaminophen and flavonoids. The enzyme activity related to this biotransformation was the highest in the contents of the caecum region of the intestine. The enzyme activity was 3.0 umole/hr/g wet feces in humans and 0.75 in rats (pH 8.0). The optimal pH was 9.0. The sulfotransferase activity was assayed in reaction mixture consisting of 60 uL of 50 mM PNS (occasionally sodium picosulfate), tyramine and 0.2 ml of the enzyme solution. Sulfatase activity was measured under the assay conditions for he sulfotransferase acitivity without the addition of the acceptor tyramine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:40:36 GMT 2023
by
admin
on
Sat Dec 16 01:40:36 GMT 2023
|
Record UNII |
95D580798S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A06AB58
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1546457
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000168459
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY | |||
|
1546458
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY | |||
|
10040-34-3
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY | |||
|
DTXSID70143251
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY | |||
|
SUB181842
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY | |||
|
5243
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY | |||
|
DB09268
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY | |||
|
95D580798S
Created by
admin on Sat Dec 16 01:40:37 GMT 2023 , Edited by admin on Sat Dec 16 01:40:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |